Vietnamese crab exporter

Oxford researchers' vaccine gives hope against coronavirus

Oxford scientists say their ChAdOx1 vaccine will be available by September. They say they're working with different groups and philanthropists to make sure it's available in places where it's needed the most.

Advertisement
Oxford researchers' vaccine gives hope against coronavirus
Illustration: Reuters

Scientists at the University of Oxford are promising a super fast vaccine against the novel coronavirus and say it will be available by September.

At a virtual press conference on Friday, the lead researcher of the vaccine development programme, Prof. Sarah Gilbert, said she and her team were confident that the ChAdOx1 vaccine can work against the coronavirus.

The Oxford vaccine group has promised one million doses of the vaccine by September.

advertisement

FOURTH TO ENTER CLINICAL TRIAL PHASE

ChAdOx1 is only the fourth Covid-19 vaccine candidate in the world to enter the clinical trial phase. But what separates it from others is the minimum time it will take to deliver mass quantities.

The other three contenders besides the Oxford group -- two American and one Chinese -- are expected to take at least 12 to 18 months to mass produce the vaccine.

Prof Gilbert said her team had been working on a Disease X, a name "given to an unknown disease which was going to come and cause a pandemic in future, and we needed to plan for it."

"With ChAdOx1 technology, already 12 clinical trials have been conducted against different diseases; we consistently see a very good vaccine safety and very strong immune response with single dose, while some other vaccine technologies such as RNA and DNA need two or more."

TEAM CONFIDENT ABOUT TRIALS

The Oxford team is so confident about its vaccine that it has already started manufacturing it, even before the clinical trials.

Oxford's Prof. Adrian Hill said the team was confident about the trials. He said they didn't want to reach a stage in September when trials were finished but they didn't have a vaccine.

"We have started at-risk manufacturing this vaccine -- not on a small scale but with a network of seven manufacturers in different places across the world," he said.

"We have three manufacturing partners in the UK, two in Europe, one China and one in India," he said.

'VERY STRONG CHANCE OF WORKING'

The three-phase trial will start with 510 volunteers, and as many as 5,000 are expected to join by the third phase.

The researchers believe their technology is safer than the other candidate vaccines, which will save a lot of time during the clinical trials and authorisation process.

"...I have worked on this technology a lot and I have worked on MERS vaccine trails and I have seen what it can do, and I think it has a very strong chance of working," Prof. Gilbert said.

Gilbert's team was awarded a £2·2 million grant from the UK's National Institute for Health Research and the UK Research and Innovation earlier this year to scale up its work.

advertisement

The team says it is working with different groups and philanthropists to make sure the vaccine is available in places where it's needed the most, including less-privileged countries.

IndiaToday.in has plenty of useful resources that can help you better understand the coronavirus pandemic and protect yourself. Read our comprehensive guide (with information on how the virus spreads, precautions and symptoms), watch an expert debunk myths, check out our data analysis of cases in India, and access our dedicated coronavirus page.

Watch India Today TV live here. Catch the latest TV debates and video reports here.

Ankit Kumar

Ankit Kumar (a.k.a. Ankiit Koomar) – Editor, Open-Source Investigations, India Today TV & Aaj Tak

Ankit Kumar is the Editor of Open-Source Investigations (OSINT) and Visual Investigations at India Today TV and Aaj Tak.  A two-time JournalismAI fellow with the London School of Economics (LSE), Ankit’s work lies at the intersection of investigative journalism and emerging digital tools as well as use of Artificial Intelligence (AI) in journalism. He has pioneered South Asia’s first dedicated OSINT journalism team, bringing cutting-edge technology into the newsroom.

His investigative reports have made national headlines and even been debated in the Indian Parliament. He was the first journalist to uncover the common link between middlemen networks in two of India’s most controversial defence deals—the VVIP AgustaWestland Chopper Deal and the Rafale Jet Deal . His reports have been frequently cited by both the Prime Minister and opposition leaders, shaping public discourse on key national security matters.

Ankit’s deep-dive investigation into the Indian Air Force’s Balakot Airstrikes was the first to feature key eyewitness accounts from the ground. 

Following his report, a UK-based dubious news portal that propagated false claims of large-scale EVM fraud in India was shut down. His stories cover a wide spectrum—from finance, business, and cybersecurity to disinformation, artificial intelligence (AI), and emerging global threats.

His work has been recognized globally, with the Global Investigative Journalism Network (GIJN) listing his reporting among the year’s top investigative stories.

🔹 Connect with him: @AnkiitKoomar on X / LinkedIn
📩 Email: [email protected]

 

READ MORE